The Physician-Focused Payment Model Technical Advisory Committee (PTAC) held a 2-day meeting on Reducing Barriers to Participation in Population-Based TCOC Models and Supporting Primary and Specialty Care Transformation.
DR. LIN: Well, welcome back. I'm Walter Lin, one of the PTAC committee members. As you may know,
PTAC will issue a report to the Secretary of HHS that will describe our key findings from
this public meeting on reducing barriers to participation in population based
total cost of care models and supporting primary and specialty care transformation.
We now have some time for the committee to reflect on what we have learned from our sessions today.
We will hear from more experts tomorrow, but we want to take the time to gather
our thoughts before adjourning for the day. Committee members, I'm going to ask you to find
the potential topics for deliberation document. It is tucked in the left front pocket of your binder.
To indicate that you have a comment to make, please flip your name tent or raise your hand in
Zoom. Josh? Would anyone like to start? (Pause.)
DR. LIN: Lauran, thank you. MS. HARDIN: Since I'm
next to you, I'll start, I'll go. So there were a lot of really interesting
themes today. I'm just going to call out a few and see if others want to comment on that. One
of the ones I thought was really interesting from a rural perspective for success, and population
based total cost of care models, is the importance of a convener, a networks approach, community
hospitals serving as sort of a community center, and the need to really share resources across
sectors to build integrated teams and have a lot of creativity around how care is delivered that
really shifts when we move to all payer models. I thought the comment Chris made about just do it,
it's time to move, you know, we've been moving things around the edges,
but in order to get to success, especially in rural, we need to have that alignment.
And then also the theme around integration of AI for broader predictive work,
the need to have proactive anticipatory disease and symptom management, as well as starting
to identify needs, pathways, and road maps for a rising risk populations for success,
we really need to be thinking about AI, as well as thinking about the tsunami of older adults,
and the declining workforce, that we need to get very efficient and be thinking about integration
of AI in all of that. And then also I just loved the last presentation. I think it's very
interesting. If we can't do this proactively in our existing structures, business is going
to step forward to make it happen, so a lot of things to consider. DR. LIN: Thank you, Lauran.
Lindsay? DR. BOTSFORD: Yes, thanks, Walter. Yes,
I mean, I think we saw some similar themes here today from previous meetings. But maybe with
some nuance that I think is worth capturing, I think hearing that multi payer alignment is
critical for success was not a new theme. But hearing some of the specifics around,
you know, what is that critical mass of patients, and somewhere between 40 and
60 percent of your patients being in these at-risk arrangements is needed to be able
to start to make it more profitable to be in these arrangements and move the needle.
I think similarly, on the multi payer framework, the idea of how could ECQMS that are multi payer
help to streamline some of the administrative burden of participation in value-based
arrangements was an interesting fact today. I think we heard challenges that we've heard
before. That technical assistance needed to participate in models remains high. And
then the burden of first year patients is also high. And how can we overcome that?
I think we also heard about the burden, the ratcheting effect. I think that is also not
a new burden. That's been pointed out. But how can we find new ways to adjust for that? I think
I'll maybe highlight just a couple, maybe more specific tactical suggestions as we think about
payments. Both longer implementation time line as we think about payment demonstration projects
in the future, as well as reducing the time between performance and payment can be helpful.
And then I think the specific tactical one I'll call out from Jessica on our first panel is that
attribution could be improved by thinking of it at the level of the TIN and MPI instead of just
the level of the TIN to avoid attribution by specialty care alone. So some real,
concrete things that we could do in improving things outside of the blow it all up and head
there faster as Dr. Kerwin. DR. LIN: Thank you,
Lindsay. I think Krishna was next. MR. RAMACHANDRAN: Yes, thank you. Yes,
to Lindsay's point too, I think there have been some themes from past discussions and
past conversations, certainly the multi payer alignment was key. And we have time coming up
in September for that should be fantastic. How do we sort of make that real nationwide? Particularly
the comments on keeping it simple, keeping the measures simple, so I think that simplicity,
noting the barrier to entry and aligning, I think, seems to be a general theme there.
Sort of the dollars for infrastructure, data popped out and clearly seem to be consistent,
technical assistance of course. And then, I think, Walter, you brought up too the last mile,
how do you make sure there are incentives get to the doctors in a way that keeps providers engaged
in the process, given the reconciliation is so long and delayed as well. I thought those were
some interesting sort of insights there as well. DR. LIN: Thank you, Krishna.
Henish? DR. BHANSALI: So I think Lindsay summarized
some of the key points that I was thinking, literally the points that I stated which,
I think, were some of the specifics around getting the lead time for the model to really prepare for
being able to participate in it, et cetera. When it comes so specialty care, I think that
what I heard is that more robust investment in primary care, and especially as we think about
the ROI for primary care and having that be a part of, sort of, the integral part of care
delivery and then aligning some of the outcomes that we have, not to negative outcomes, right.
So someone goes to get a knee replacement or hip replacement. They're not walking out with a with
a DVT but actually outcomes that are aligned with what the positive outcomes are expected to be,
such as mobility, or functionality, et cetera. There's an organization called the International
Consortium of Health Outcomes Management that specifically states, what are the positive
outcomes that you would want from a lot of these interventions. And that's at least
what I heard the clinician document, comment on. And so as we're thinking about quality metrics,
measurable quality metrics, to think of them not as the avoidance of negative things,
but really as a promotion of positive things that we hope for our patients.
And then the last piece I heard about was advanced payer planning. And so advanced payer planning,
being a part of any value-based current model, just fundamentally changes how
that model is practiced. And this has been demonstrated multiple times. And I
think it was shared a couple of times. Having that be a core quality metric
can also be a consideration. DR. LIN: Thank you, Henish.
Lee? DR. MILLS: Very similar,
some of these have already been said. But I was really struck by the richness and the
intentionality our first panel discussion first thing in the morning brought to this. They had
some very concrete, very specific recommendations which is what we asked them to give us.
And some of those have already been mentioned on just the criticality of the new cashflow in the
first few months, the timeline being too long of 12 to 18 months, and how you try to shorten
that. But then the risk-taking organization might help get you over that, you know, one quarter hump
where you can start operating. Attribution is mentioned.
I thought the concept was interesting that the complexity we talked a lot about complexity
over the last three or four years. But just the complexity is so overwhelming, and the inertia
is so entrenched that you financially have to be far beyond the tip point to actually tip.
You know, we had examples of, you know, very favorable arrangements offered to physicians
to move out of fee for service. And they're just so fearful of change and so entrenched
with the inertia and systems that you have to be not, you know 55, 44 is enough to get you
tipped. You've got to be maybe 75 percent before you think about even considering changing how
you practice, which was powerful to hear. I thought the point that rural providers
that are, you know, traditionally pretty low volume, bring a whole new set of standards,
and the power of low numbers and risk goes up in that setting. I thought that was powerful.
Several people said different ways that, you know, MSSP is, you know, clearly kind of a winning model
in the Medicare space but that it lacks one key thing, which was essentially the ability to do UM,
to work on demand utilization control upstream or utilization control in the organization as a way
to weed out waste and unnecessary costs. I thought that was interesting. I hadn't heard that before.
I thought it was interesting to hear that, again, back to the risk concepts that people
think actually that how the downside risk is mitigated, and control is
actually more important that how much gain is possible. That was a more important concept.
Again, really struck by several speakers speaking to that a margin of 40 or 50 percent more is
needed before you consider it. And that it takes 40 to 50 percent of your practices into our panel
in a multi payer alignment to think about tipping over and changing the operations.
I'll point out, I think that Clif's materials from NAACOS, he's done some really nice thinking
about bench marking issues we've talked about, and challenges with some offered solutions that
I appreciated, that about risk adjustment and trend adjustment that are worth consideration.
And then the quote of the day from Dr. Sinopoli that really, in your physician leadership,
moving to value based care, it takes a madman. So may we all be
the madmen in our arenas. DR. LIN: Thank you, Lee.
I think Jim was next. DR. WALTON: Yes, just to try to
fill in some gaps, you probably would expect me to say something about the rural infrastructure
problems in America, so I will. (Laughter.)
DR. WALTON: So I don't want to really disappoint anybody. You know, the big thing that I took away
was it's really, really hard to innovate when your ship's got holes in it.
And we heard pretty load and clear, we continue to hear this over and over again from experts
in the field that, you know, there is a pretty large issue out in the United States that we,
as we talk about value based care and expansion of it, and increasing participation, and creating
pathways for increasing participation, so that the benefits of value based care would
accrue to people that are really vulnerable. So if you think about all of that, you know, we
say well, let's go for the target. And I think we heard that from Chris, you know, to target this.
And we had an observation of, you know, we had a lot of people here that were really
highly engaged in doing this work and very excited about it. And we heard from Elizabeth
in California that the purchasers, if you will, want to move this way as well.
So there's kind of this momentum accruing in large environments, but there's a group of people that
are probably likely to be left behind. And so I think that, given what we said about market
forces and organizational structures, and business models that could affect participation decisions,
we see critical access hospitals and rural providers being at somewhat of a disadvantage.
And so I would submit that, like we had talked about having a pathway for value
based care aggregators, we actually might want to think about advising a particular pathway for
the rural communities where the infrastructure is healthcare infrastructure is kind of falling down,
not because of value based care, but in spite of it. I also thought there was one other thing
that I wanted to lift up was the idea of a measure being the patients' goal attainment and being kind
of a lining, if you will, performance measures across multiple payers in that particular vein,
I thought was really, really strong and something I took away from today.
And if I only I guess there's this thing with Medicare Advantage that seems to have
some kind of advantage. And there's a little bit of a wringing of the hands to some extent
around the fact that there's more business moving away from fee for service and into
Medicare Advantage. And we see that fee for service value based care is saving money and
producing increased quality in the MSSP model. So we're thinking well, could it be cannibalizing
value? Well, maybe there are some policy opportunities to recommend to kind of stop some
of the that disadvantage that or the advantage for Medicare Advantage with regard to risk scoring,
for example, and some of the ratcheting effects that are adversely affecting the
fee for service of value based care. So I'll leave it at that. And thank you very much.
DR. LIN: Thank you, Jim. Larry? DR. KOSINSKI: I compiled my notes here,
and what I have, number one, there must be a feasible, visualizable path to savings. So
it's got to be attainable. You've got to be able to see that you can do it.
The time between performance and payment must be reduced. Up front payments have to
be part of the model. We still don't have enough real participation from
specialists. I love the line most specialists participate in ACOs are really not in the ACO.
Fee for service still has to be made less desirable for the specialist and more
desirable for the PCP. Hybrid fee for service capitation models need to be investigated.
The 40 percent rule may be the way to get participation. You've got to get the hearts
and minds. Enough of their revenue has to be at risk or part of the and we heard 40 percent a
couple of times. Risk reward analysis has to be realistic and consistent with the business
model of the practice. Multi payer alignment could be a game changer for participation.
And then finally, and something that came out near the end that I thought was cool,
nested PCMHs may be a way to create cascading accountability for chronic medical care. I thought
that was cool. That's what I wrote down. DR. LIN: Thank you, Larry.
And Chinni? DR. PULLURU:
Great job, everybody. I'm going to try to fill in some of the gaps that I haven't heard yet.
And one of them is from the first panel. They spoke about rural hospitals and the
global payment and how well that had worked. And perhaps that's the way to sort of salvage and
rescue some of the hospitals that are very needed in those areas right now and differentiate that.
One of my favorite quotes was that primary care physicians have a Stockholm
syndrome when it comes to (Simultaneous speaking.)
DR. PULLURU: when it comes to fee for service. And as a primary care physician who practiced,
I can tell you that's absolutely true. But I like the idea, and I haven't heard
this in all the time that I've been on PTAC, is making the primary care payment tax deductible
for the patient because of the ROI on primary care being $13 to $1, I think that's an excellent idea.
I also love the idea of sort of a carve out, some people called it a sub cap for primary care,
some people called it subscription payment, but a carve out payment as a mechanism for
potentially a perspective type of payment to help primary care physicians do what they
need to do and provide that $13 to one ROI. And then a few other things, the technical
assistance to implement programs, I do think that's really important,
particularly in areas, you know, so we don't incentivize consolidation inadvertently to
programs, because people just can't have access to data or the technical assistance.
And then I think I have one more. The other thing that I noted was having actuarial stability.
So as you look at benchmarking, and you go through actuarial analysis, retrospectively
and prospectively, and you're trying to get into programs, figuring out a way that the provider
systems or providers have some level of actuarial stability in benchmarking, and having some sort of
reconciliation that's quick so they can actually get access to the money when they fall short.
And then I, you know, of course, Angelo, our favorite person, brought up the 2020
OIG rules around the flexibility in waivers. And I think looking at that program to say, like,
hey, that was great, why aren't people using it, and how do people how do we make that more
a part of the sort of connective tissue of how care is delivered? DR. LEE: Thank you, Chinni.
Josh? DR. LIAO: Thanks,
Walter. Really great session, and I go with what other committee members have said. And many things
bounce around in my mind. I think, you know, I return to kind of what we started with today
around kind of barriers to participation. I kind of alluded to this idea of maybe
thinking about us optimizing as opposed to maximizing, insomuch as that I think
these population based total costs of care models, I think, can and should be improved
in a technical way, like PTAC is supposed to be looking at to be one key offering in the
market. But as others have alluded to, there are others that I think are really important.
And as I reflect on many conversations leading up to this session, you know,
there is so much good stuff that people have said. And where my mind is, it's kind of,
like, do I need ten other really good things added to the conversation, or are there things
you might take away from the conversation, addition by subtraction. They're like things
that make sense but, if you really think about it, actually don't serve us as we're trying to
achieve these goals with population based models. And really, kind of, to me it comes back down to
tradeoffs. So while I really appreciate a lot of the kind of concepts mentioned,
I think we should really stare honestly and transparently at some of these tradeoffs.
So for example, you know, multi payer, I think good for any number of reasons,
other people have mentioned it multiple times, but it requires a simplicity, right. And that
simplicity though, I think, has come at a tradeoff, historically,
right. The simplicity can be achieved with primary care and ambulatory measures which
is predominantly what many of these models have been historically, however named.
But we struggle with investment in primary care. How can you bring that simplicity to
specialty care when every specialist is a little bit different, and the context is different? And
the specialty kind of load, or the dose you would need for different populations is different.
I think we just have to recognize that things that require simplicity, like multi payer alignment,
will struggle when you're trying to integrate sub specialists. And I think, you know, to the
extent that one ounce of data is better than a ton of opinion, if you look at what we've done,
really well intended efforts over a decade in Medicare, you see that with multiple models,
what doesn't port over to Medicaid, what doesn't port over to commercial space.
I know some of the committee members have really focused on advancing specialty models
in the commercial space. Those don't really carry over very easily to others as well. I
think that's telling us something. And so the more we say multi payer,
keep it simple but, yes, integrate all specialists, I think that notion doesn't
serve us anymore. And I think three or four of these meetings suggest we should do away with
some of that thinking to help us, you know, do both things, like some of our SMEs have suggested.
Here's another, I'll just give you one more for time. When we
think about scaling up participation, say within a payer such as Medicare, you know,
what's the tradeoff between that then and the multi payer that I just mentioned?
Getting more people into different models and one payer doesn't necessarily get us
why wider with multi payer. Because others have mentioned today this idea of one size won't fit
all. So if you scale up, you are accepting complexity. The table we've put forward on
the PCDT has got complexity in it, meaning it's got multiple rows and multiple columns.
I think this is a feature, this is not a defect in the system. But if we embrace that complexity,
we have to set aside some degree of simplicity, right. So scaling up within a payer, I think,
and scaling out wide, there is a tradeoff there. And so I think they're just, as I've been thinking
through this, maybe I'll kind of summarize more tomorrow, but there are three or three
or four or five things in my head where I think expunging these ideas from our conversation going
forward will help us. Because we heard, over many meetings, including today, really nice things. But
how do they fit together? And I worry some don't. And so I really love the conversation. I think
this all really helpful for moving the dialogue forward. I look forward to thinking more about the
technical pieces with the rest of the committee members and the subject matter experts. But what
are those ideas that don't serve us anymore that we need to take off the table. That's where my
head is at after a really productive day. Thanks. DR. LEE: Thank you, Josh. And just in the interest
of time, I'll just make a couple of really brief remarks in terms of my thoughts. You know,
after Jim's PCDT presentation, that went really well, the plateauing of
participation in PCDT or C models, ACOs. You know, I had said fee for service is the real
villain here. And I think that was a theme that ran strongly through the sessions today. Since,
I think Chinni quoted Dr. Crow's Stockholm syndrome of fee for service, or used the other
one, fee for service is the devil to the PCP, all the way through, to the very last session
where Elizabeth said the muscle memory of fee for service is very strong, you know.
And I think the idea that there are viable business models that thrive under fee for service,
I think, presents a real challenge to increasing participation in value based care.
The other thing I just mentioned along those same lines is the comment by Clif Gaus around
how ACOs are held to stricter financial performance expectations without approaches
like no networks or utilization management. And I think that's also very important to
grasp as well. Because, you know, if total cost of care models were entering into a boxing ring
with fee for service, it's like we're entering into the boxing ring with one arm tied behind
our back. We don't have the tools that Medicare Advantage plans have to make these models succeed.
And so I just think there might need to be additional considerations over time
about adding tools to the PB TCOC toolbox to help these models be more successful.
With that, I'm going to turn the time over to Chinni to close us out.
* Closing Remarks DR. PULLURU: Before closing
I'd like to check with the staff team to see if they have any clarifying questions for us.
I want to thank everyone for participating today, our expert panelists, my PTAC colleagues, and
those listening in. We will be back tomorrow at 9:00 a.m. Eastern time. We will be joined by Mr.
Abe Sutton, the Director of Center for Medicare and Medicaid Innovation, and Deputy Administrator
for the Center for Medicare and Medicaid Services, who will be providing opening remarks.
Our day two agenda features a panel discussion and final listening session.
The panel discussion will focus on enhancing the ability of population based total cost
of care models to be competitive. Then listening Session 3 will focus
on how to maximize participation of beneficiaries in accountable care
and improve the sustainability of effective population based total cost of care models.
There will also be an opportunity for public comments tomorrow afternoon
before the meeting concludes with the committee discussion.
We hope you'll join us then. Thank you. This meeting is adjourned for the day.